Related Experiment Video
Updated: Jul 14, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases
F G Mastronardi1, H Tsui, S Winer
1Department of Structural Biology and Biochemistry, The Hospital for Sick Children, University Health Network, Toronto, Ontario, Canada. fabrizio@sickkids.ca
Abstract:
Progressive demyelination in multiple sclerosis (MS) reflects the negative balance between myelin damage and repair due to physical and molecular barriers, such as astrocytic glial scars, between oligodendrocytes and target neurons. In this paper, we show that combination therapy with paclitaxel (Taxol) plus the universal methyl-donor, vitamin B12CN (B12CN), dramatically limits progressive demyelination, and enhances remyelination in several independent, immune and nonimmune, in vivo and in vitro model systems. Combination therapy significantly reduced clinical signs of EAE in SJL mice, as well as the spontaneously demyelinating ND4 transgenic mouse. Astrocytosis was normalised in parallel to ultrastructural and biochemical evidence of remyelination. The combination therapy suppressed T cell expansion, reduced IFN-gamma, while enhancing IFN-beta and STAT-1 expression, STAT-1 phosphorylation and methylation of STAT-1 and MBP in the brain. Paclitaxel/B12CN has nearly identical effects to the previously described combination of IFN-beta/ B12CN, whose clinical usefulness is transient because of IFN-neutralising antibodies, not observed (or expected) with the present drug combination. This report provides a mechanistic foundation for the development of a new therapeutic strategy in humans with MS.
Insights
Combination therapy with paclitaxel and vitamin B12CN significantly limits demyelination and enhances myelin repair in multiple sclerosis models. This approach offers a promising new therapeutic strategy for progressive multiple sclerosis (MS).
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Progressive demyelination in multiple sclerosis (MS) is driven by an imbalance between myelin damage and repair.
- Physical and molecular barriers, like astrocytic glial scars, impede oligodendrocyte-neuron communication and myelin repair.
Purpose of the Study:
- To investigate the efficacy of combination therapy with paclitaxel and vitamin B12CN (B12CN) in limiting demyelination and enhancing remyelination.
- To explore the mechanistic basis of this combination therapy in various experimental models of MS.
Main Methods:
- Utilized independent in vivo and in vitro model systems, including experimental autoimmune encephalomyelitis (EAE) in SJL mice and the ND4 transgenic mouse model.
- Assessed clinical signs, astrocytosis, ultrastructural and biochemical markers of remyelination, T cell expansion, and cytokine profiles (IFN-gamma, IFN-beta).
- Analyzed STAT-1 expression, phosphorylation, and methylation of STAT-1 and myelin basic protein (MBP).
Main Results:
- Combination therapy with paclitaxel/B12CN dramatically limited progressive demyelination and enhanced remyelination across multiple models.
- Therapy normalized astrocytosis and showed ultrastructural and biochemical evidence of myelin repair.
- Suppressed T cell expansion, reduced IFN-gamma, and increased IFN-beta, STAT-1 expression, STAT-1 phosphorylation, and methylation of STAT-1 and MBP.
Conclusions:
- Paclitaxel/B12CN combination therapy provides a potent strategy for limiting demyelination and promoting remyelination in MS.
- The observed effects are mechanistically similar to IFN-beta/B12CN but without the risk of neutralizing antibodies.
- This provides a foundation for developing a novel therapeutic approach for human MS.
